An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193

Trial Profile

An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2015

At a glance

  • Drugs Crotedumab (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 12 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Aug 2014 Planned End Date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov
    • 21 Aug 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top